



Financial Statements
for the 1st quarter of fiscal year ending March 31, 2017
(From Apr. 1, 2016 to Jun. 30, 2016)

Summary of consolidated results

JMS Co., Ltd.

Company Code No. 7702

August 5, 2016

Highlights in Business Results



(unit: JPY million)

	Results Apr. - Jun. 2015	Results Apr. - Jun. 2016	Diff.	Year- over - Year
Sales	13,841	13,336	(505)	(3.7%)
Operating Income	57	121	63	109.4%
Ordinary Income	(11)	209	221	—%
Profit attributable to owners of parent	14	84	69	466.7%
Net Income per share	JPY 0.30	JPY 1.72	---	---

Exchange Rate (average during period)	US Dollar	121.36	108.14
	Euro	134.18	127.23
	Singapore Dollar	90.34	79.56

(unit: JPY)

Decreased in sales, but increased in profit(2th straight year) for the 1st Quarter of FYE Mar. 2017

Sales	Japan	-Increased sales of Enteral nutrition system products -Declined sales of hemodialysis machines
	Overseas	-Continued growth in the sales of apheresis kits -Influence of the strong yen in foreign currency translation


Profit	-Increased sales of high value-added products
--------	---

Sales by segment (geographical area)

(unit: JPY million)

Apr. – Jun. 2015


Apr. – Jun. 2016



Profit by segment (geographical area)

(unit: JPY million)

Apr. – Jun. 2015
 Apr. – Jun. 2016



Summary by segment (geographical area)



Japan

Sales	9,921 JPY mil.	(0.3%)
Ordinary loss	(10) JPY mil.	—%

-Increased sales of Enteral nutrition system products were offset by the declined sales of hemodialysis machines, reducing net sales
 -Despite the increase of sales of high value-added products, the increase of depreciation burden resulted in a loss



Southeast Asia

Sales	4,675 JPY mil.	(7.8%)
Ordinary Income	214 JPY mil.	—%

-Continued growth in the sales of apheresis kits for North America was offset by decrease in yen translation with strong yen, reducing net sales
 -The influence of sales increase on a local currency basis led to a profit



China

Sales	952 JPY mil.	2.2%
Ordinary Income	62 JPY mil.	—%

-Strong sales of Infusion Set for Japan market raised net sales
 -The sales increase led to a profit

(%: year-over-year)



Enteral Nutrition Systems

Enteral Nutrition Systems is designed for use when providing nutrition treatment (which uses a tube to send nutrients directly into the patient's body) to patients who have difficulty absorbing nutrients through standard meals.

Summary by segment (geographical area)



Germany

Sales	800 JPY mil.	0.1%
Ordinary Income	59 JPY mil.	(2.0%)

-Strong sales of AV fistula needles for the domestic market raised net sales
 -Higher import cost with weak Euro resulted in a profit



United States

Sales	587 JPY mil.	(20.9%)
Ordinary Income	18 JPY mil.	45.1%

-Weak sales of AV fistula needles for North America market reduced net sales
 -The decrease of selling, general and administrative expenses raised a profit



Others

Sales	426 JPY mil.	(18.1%)
Ordinary loss	(148) JPY mil.	— %

(%: year-over-year)



AV Fistula Needle

AV fistula needle is for pulling blood from a patient during a dialysis therapy.


Sales by Business Segment



(unit: JPY million)

Apr. – Jun. 2015


Apr. – Jun. 2016



Sales by Segment (Customer's Location)

(unit: JPY million)


Apr. – Jun. 2015 Apr. – Jun. 2016



Selling, General and Admin. Expenses



(unit: JPY million)




(unit: JPY million)

	Apr. - Jun. 2015	Apr. - Jun. 2016	Diff.	Year-over-Year
Labor Cost	1,447	1,442	(5)	(0.3%)
Transport	401	380	(21)	(5.3%)
R & D	283	335	51	18.3%
Depreciation	101	104	2	2.8%
Others	1,075	1,047	(27)	(2.6%)
Total	3,308	3,308	0	0.0%

Ordinary Income : Compared with the previous year



(unit: JPY million)



The underlined figures exclude impact of exchange rate.

Forecast for FYE Mar. 2017



(unit: JPY million)

	FYE Mar. 2016 Result	FYE Mar. 2017 Forecast	Year-over-Year
Sales	57,636	58,000	0.6%
Operating Income	1,422	1,100	(22.7%)
Ordinary Income	1,252	1,100	(12.2%)
Profit attributable to owners of parent	754	600	(20.5%)
Net Income per share	JPY 15.48	JPY 12.31	---

Exchange Rate (average during period)

US Dollar	120.14	110.00	---
Euro	134.31	125.00	---
Singapore Dollar	86.70	82.00	---

Influence of appreciation of the yen, reduction in reimbursement price, and depreciation burden due to new plant establishment and plant extension is estimated. Strive to develop to the business promptly with increased production capacity.

Topics < Apr. 2016 – Jul. 2016 >



- Launching new product “Oxia ACF” , Filter -integrated membrane oxygenator
Jul. 21, 2016
- Holding the completion ceremony of the new facility of Izumo Plant.
May. 6, 2016
- Holding the inauguration ceremony of JMS Healthcare PHL, Inc. .
Apr. 25, 2016



「Oxia ACF」



Izumo Plant

A white building of the top right corner the new facility



JMS Healthcare PHL, Inc.



The Bridge to Good Health Care

The assessment figures described on this report are based on available information at this moment, including uncertain data. Actual results may be different from the figures.